Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place

被引：2
|
作者：
Meerveld-Eggink, A. [1 ]
Graafland, N. [2 ]
Wilgenhof, S. [1 ]
Van Thienen, J. V. [1 ]
Grant, M. [3 ]
Szabados, B. E. [4 ]
Abu-Ghanem, Y. [5 ]
Boleti, E. [6 ]
Blank, C. U. [1 ]
Haanen, J. B. A. G. [1 ]
Powles, T. B. [7 ]
Bex, A. [8 ]
机构：
[1] Antoni van Leeuwenhoek Hosp NKI AVL, Dept Med Oncol, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Urol, Amsterdam, Netherlands
[3] Queen Mary Univ London, Med Oncol, Barts Canc Inst, London, England
[4] Barts Canc Inst, Dept Med Oncol, London, England
[5] Royal Free London NHS Fdn Trust, Urol, London, England
[6] Royal Free Hosp, Acad Oncol Dept, Sch Med, London, England
[7] St Bartholomews Hosp, Oncol, London, England
[8] Antoni van Leeuwenhoek Hosp NKI AVL, Netherlands Canc Inst, Surg Oncol Urol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.809
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
737P
引用
收藏
页码：S575 / S575
页数：1
相关论文
共 50 条
  • [31] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [32] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [33] Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma
    Zarrabi, Kevin K.
    Vaishampayan, Ulka
    Barata, Pedro C.
    EUROPEAN UROLOGY FOCUS, 2024, 10 (06): : 879 - 881
  • [34] Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients
    Ohba, Kojiro
    Nakanishi, Hiromi
    Kawada, Ken
    Nakamura, Yuichiro
    Mitsunari, Kensuke
    Matsuo, Tomohiro
    Mochizuki, Yasushi
    Imamura, Ryoichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 827 - 832
  • [35] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [36] Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.
    Dzimitrowicz, Hannah Elizabeth
    Schwartz, Fides
    Infield, Jordan
    Zhang, Dylan
    Ho, Ethan
    Wu, Yuan
    Gupta, Rajan T.
    Harrison, Michael Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16517 - E16517
  • [37] Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).
    Lemelin, Audreylie
    Takemura, Kosuke
    Ernst, Matthew Scott
    Wells, J. Connor
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Davis, Ian D.
    Wood, Lori
    Pal, Sumanta Kumar
    Hansen, Aaron Richard
    Kollmannsberger, Christian K.
    Bjarnason, Georg A.
    Tran, Ben
    Li, Haoran
    Kanesvaran, Ravindran
    Powles, Thomas
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Association of microbiome to nivolumab response in metastatic renal cell carcinoma (mRCC)
    Maia, Manuel
    Poroyko, Valeriy
    Won, Hae
    Bergerot, Paulo
    Almeida, Lorena
    Dizman, Nazli
    Hsu, JoAnn
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [39] Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma
    Kato, Taigo
    Fujita, Kazutoshi
    Nagahara, Akira
    Nakata, Wataru
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Takada, Shingo
    Nishimura, Kensaku
    Tsujihata, Masao
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    Uemura, Motohide
    Uemura, Hirotsugu
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2023, 34 : S1412 - S1412
  • [40] Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.
    Meza, Luis A.
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Dorff, Tanya B.
    Lyou, Yung
    Frankel, Paul Henry
    Llamas, Marian
    Hsu, Joann
    Zengin, Zeynep Busra
    Salgia, Nicholas
    Malhotra, Jasnoor
    Chawla, Neal Shiv
    Gillece, John D.
    Reining, Lauren J.
    Trent, Jeffrey M.
    Takahashi, Motomichi
    Oka, Kentaro
    Higashi, Seiya
    Highlander, Sarah K.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345